Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and strategic changes. Analyst John Athanasiou from Red Leaf Securities suggests CSL shares are oversold, ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM Follow our Australia news live blog for latest updates Get our breaking ...

Good morning, ladies and gentlemen. We still have some people registering, but we always start our Board meetings on time at CSL. So today will be no exception. Welcome to CSL's 2025 Annual General ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

CSL (ASX:CSL) has attracted fresh attention after its Broadmeadows plasma fractionation facility in Australia was named the Overall Winner of the 2025 Facility of the Year Award by the International ...

CSL has partnered with Dutch biotech VarmX to co-develop VMX-C001, a potential first-in-class treatment to restore blood coagulation in patients on FXa inhibitors. The agreement includes an upfront ...